In women older than 60, does estrogen‑progestogen hormone therapy prevent osteoporosis?

Hormone Therapy for Osteoporosis Prevention in Women Over 60

While estrogen-progestogen therapy effectively prevents osteoporosis and reduces fracture risk by 20-40% at all bone sites, it should NOT be used as first-line therapy in women over 60 solely for osteoporosis prevention due to an unfavorable benefit-risk profile at this age.

The Evidence-Based Rationale

The U.S. Preventive Services Task Force guideline explicitly states that FDA-approved indications for hormone therapy are limited to treatment of menopausal symptoms and prevention of osteoporosis, but includes a black box warning requiring "the lowest effective dose and for the shortest duration of use consistent with treatment goals and risks" 1. Critically, the WHI trial enrolled women with an average age of 64 years—well past menopause onset—and post hoc analyses suggest increased probability of harm with increasing age at initiation, though not always reaching statistical significance 1.

Why Age Matters

The timing of hormone therapy initiation is crucial:

• Early postmenopause (within 2-3 years): Hormone therapy prevents the rapid bone loss that is maximal during this period and may have a more favorable benefit-risk profile 2
• Women over 60: The balance shifts unfavorably due to increased risks of breast cancer, cardiovascular disease, stroke, and venous thromboembolism that accumulate with age 1, 3

What Should Be Used Instead

For women over 60 with osteoporosis or high fracture risk, the guideline recommends alternative effective interventions 1:

• Bisphosphonates (first-line for most patients over 60)
• Denosumab
• Weight-bearing exercise
• Calcitonin
• Newer agents like romosozumab for very high-risk patients 4

The One Exception

Hormone therapy may be considered in women over 60 ONLY if:

• They are already taking it for menopausal symptoms that persist into their 60s, AND
• They have osteopenia or osteoporosis requiring treatment, AND
• They have no contraindications, AND
• Alternative osteoporosis medications are not suitable

In this scenario, continuing therapy serves dual purposes, but requires ongoing reassessment of the benefit-risk balance 2.

Common Pitfall to Avoid

Do not initiate hormone therapy in a woman over 60 who is asymptomatic from menopause simply because she has osteoporosis. The WHI data specifically studied this population and found the risks outweigh benefits 1. The 20-40% fracture reduction 2 does not justify the increased cardiovascular and cancer risks in this age group.

The Practical Algorithm

For women over 60 with osteoporosis:

1. Screen for fracture risk using DEXA and FRAX scores 5
2. First-line treatment: Bisphosphonates or denosumab
3. Ensure adequate calcium (1200 mg/day) and vitamin D supplementation
4. Reserve hormone therapy only for those already taking it for persistent menopausal symptoms
5. Consider anabolic agents (teriparatide, abaloparatide, romosozumab) for very high fracture risk 4

The evidence is clear that while hormone therapy works for bone protection, other safer alternatives exist for women over 60, making it inappropriate as a primary osteoporosis prevention strategy in this age group 1, 5.